| Name | Title | Contact Details |
|---|
Bigelow is the M + A Advisor exclusively for owners of high-performing private companies — Entrepreneur Owner-Managers with their skin in the game. Our scrappy boutique firm behaves as one collaborative team. Leveraging our independence and exclusive EOM focus, we have helped hundreds of clients build and capture Enterprise Value while respecting their values, their legacy and the intersection of their professional and personal goals. Frequently our work with clients goes on for years in advance of a wealth-building transaction. Unlike virtually all of the firms with which we compete, we are independently owned. We have only one source of revenue — our Entrepreneur Owner-Manager clients. No referral fees. No investing, trading, lending, or underwriting. No buy-side advisory. No products to sell. No conflicts. We aspire to be completely aligned with achieving our clients potential, striving endlessly to be masters of our craft.
Smith Power Products, Inc. is a leading distributor and service provider of heavy-duty and semi-truck parts, repair, and maintenance in the Western United States. Founded in 1952 and headquartered in Salt Lake City, Utah, the company employs approximately 270-360 people and generates annual revenue of $93 million. The company offers a range of services, including heavy-duty and semi-truck repair, 24-hour emergency service, full maintenance agreements, machine shop services, and engine repowering to meet emission standards. Smith Power Products is an authorized distributor for major manufacturers such as mtu-Rolls-Royce, Detroit-Diesel, and Allison Transmission, and is part of the WheelTime network for quality parts distribution. With six distribution centers across the Western United States, the company ensures prompt delivery of spare parts and technical support to a diverse customer base, including mining companies, oil field contractors, and government agencies.
Clinton Community College (CCC) is a two-year community college located in Clinton, Iowa, founded in 1946. Initially serving veterans returning from World War II, CCC is part of the Eastern Iowa Community Colleges system. The college offers a range of educational programs, including Associate in Arts/College Transfer Classes, Career Technology Programs, and Continuing Education courses aimed at personal and professional development. The main campus is situated at 1000 Lincoln Boulevard, with additional facilities including the CCC Technology Center and the Maquoketa Center, which provide various educational opportunities. CCC also has intercollegiate athletics, featuring mens basketball and womens volleyball teams known as the Cougars. The Paul B. Sharar Foundation supports the college by providing scholarships and funding for students and faculty, enhancing the educational experience at CCC. The college is accredited by the North Central Association of Colleges and Schools, ensuring high educational standards.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.